Overview

A Relative Bioavailability Study of Fentanyl 25 μg/h Transdermal System

Status:
Completed
Trial end date:
2003-06-01
Target enrollment:
Participant gender:
Summary
To compare the rate and extent of absorption of fentanyl 25 μg/h transdermal system (test) and Duragesic (reference) administrated as 1 x 25 μg/h single transdermal system application.
Phase:
Phase 1
Details
Lead Sponsor:
Actavis Inc.
Treatments:
Fentanyl